Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial

Clinical Neuropharmacology - Tập 41 Số 5 - Trang 151-155 - 2018
Tsuyoshi Miyaoka1,2,3,4, Misako Kanayama1,2,3,4, Rei Wake1,2,3,4, Sadayuki Hashioka1,2,3,4, Maiko Hayashida1,2,3,4, Michiharu Nagahama1,2,3,4, Shihoh Okazaki1,2,3,4, Satoko Yamashita1,2,3,4, Shingo Miura1,2,3,4, Hiroyuki Miki1,2,3,4, Takuji Ohigashi1,2,3,4, Masahiro Koike1,2,3,4, Muneto Izuhara1,2,3,4, Tomoko Araki1,2,3,4, Keiko Tsuchie1,2,3,4, Ilhamuddin Abdul Azis1,2,3,4, Ryosuke Arauchi1,2,3,4, Rostia Arianna Abdullah1,2,3,4, Arata Oh‐Nishi1,2,3,4, Jun Horiguchi1,2,3,4
1Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.
2Department of Psychiatry, Shimane University School of Medicine, Izumo, Japan
3e-mail: [email protected]
4This trial was registered with UMIN (number 000028341).

Tóm tắt

Aim Up to 60% of depressed patients do not obtain sufficient relief from a course of antidepressant therapy, and these treatment-resistant major depressive disorder (TRD) patients are at increased risk for relapse, chronicity, persistent psychosocial impairments, and suicide. Probiotics actively participate in treatment of neuropsychiatric disorders. However, the role of gut microbiota in brain disorders and depression remains unclear. We performed a prospective study to evaluate the effects of Clostridium butyricum MIYAIRI 588 (CBM588). Methods This was an 8-week open-label study to evaluate the efficacy and safety of CBM588 in combination with antidepressants in adult patients diagnosed with TRD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Forty antidepressant-treated inpatients were included. Patients were randomized to adjuvant treatment with CBM588 (n = 20) or control (n = 20). The primary endpoint was the change in the 17-item Hamilton Depression Rating Scale score from baseline to week 8. Secondary end points were changes in the Beck Depression Inventory and the Beck Anxiety Inventory scale scores from baseline to week 8. The Systematic Assessment of Treatment Emergent Events—General Inquiry was used to assess adverse effects. Results CBM588 (60 mg/d) in combination with antidepressants (flvoxamine, paroxetine, escitalopram, duroxetine, and sertraline) provided significant improvement in depression. All patients completed the trial, and 70% responded to treatment; the remission rate was 35.0%. No serious adverse events occurred. Conclusions These preliminary data suggest that CBM588 in combination with antidepressants is effective and well tolerated in the treatment of TRD. Further studies using a larger, double-blind, parallel-group design are warranted to confirm these findings.

Từ khóa


Tài liệu tham khảo

2004, The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation, Psychol Med, 34, 73, 10.1017/S0033291703001107

2017, Can gut microbes play a role in mental disorders and their treatment?, Psychiatr Danub, 29, 28, 10.24869/psyd.2017.28

2016, Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial, Nutrition, 32, 315, 10.1016/j.nut.2015.09.003

2011, Gut microbiota and diabetes: from pathogenesis to therapeutic perspective, Acta Diabetol, 48, 257, 10.1007/s00592-011-0333-6

2013, Melancholic microbes: a link between gut microbiota and depression?, Neurogastroenterol Motil, 25, 713, 10.1111/nmo.12198

2009, Traumatic brain injury and intestinal dysfunction: uncovering the neuro-enteric axis, J Neurotrauma, 26, 1353, 10.1089/neu.2008.0858

2003, Alterations of intestinal mucosa structure and barrier function following traumatic brain injury in rats, World J Gastroenterol, 9, 2776, 10.3748/wjg.v9.i12.2776

2015, Bifidobacteria modulate cognitive processes in an anxious mouse strain, Behav Brain Res, 287, 59, 10.1016/j.bbr.2015.02.044

2015, Small intestine dysfunction in Parkinson's disease, J Neural Transm, 122, 1659, 10.1007/s00702-015-1442-0

2015, Gastrointestinal autonomic dysfunction in patients with Parkinson's disease, J Mov Disord, 8, 76, 10.14802/jmd.15008

2015, Brain-gut-microbiota axis in Parkinson's disease, World J Gastroenterol, 21, 10609, 10.3748/wjg.v21.i37.10609

2006, Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy, J Clin Gastroenterol, 40, 264, 10.1097/00004836-200603000-00020

2008, Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice, Diabetes, 57, 1470, 10.2337/db07-1403

2009, Lactobacillus fermentum ME-3 — an antimicrobial and antioxidative probiotic, Microb Ecol Health Dis, 21, 1

2011, Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers, Gut Microbes, 2, 256, 10.4161/gmic.2.4.16108

2011, Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects, Br J Nutr, 105, 755, 10.1017/S0007114510004319

1984, The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants, Microbiol Immunol, 28, 975, 10.1111/j.1348-0421.1984.tb00754.x

1997, Intestinal distribution and intraluminal localization of orally administered Clostridium butyricum in rats, Microbiol Immunol, 41, 665, 10.1111/j.1348-0421.1997.tb01909.x

1999, Probiotic bacteria stimulate gut epithelial cell proliferation in rat, Dig Dis Sci, 44, 2119, 10.1023/A:1026647024077

2000, Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats, J Gastroenterol, 35, 341, 10.1007/s005350050358

2001, Butyrate suppression of colonocyte NFκB activation and cellular proteasome activity, J Biol Chem, 276, 44641, 10.1074/jbc.M105170200

2003, Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI, Pediatr Int, 45, 86, 10.1046/j.1442-200X.2003.01671.x

2004, The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice, FEMS Immunol Med Microbiol, 41, 219, 10.1016/j.femsim.2004.03.010

2015, Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats, J Psychiatr Res, 61, 114, 10.1016/j.jpsychires.2014.11.003

2007, Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action, J Pharmcol Experiment Therapeutics, 321, 892, 10.1124/jpet.107.120188

1980, Rating depressive patients, J Clin Psychiatry, 41, 21

1961, An inventory for measuring depression, Arch Gen Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004

1988, An inventory for measuring clinical anxiety: psychometric properties, J Consult Clin Psychol, 56, 893, 10.1037/0022-006X.56.6.893

1986, SAFTEE: a technique for the systematic assessment of side effects in clinical trials, Psychopharmcol Bull, 22, 343

2004, Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics, Curr Drug Targets, 5, 279, 10.2174/1389450043490514

2012, Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut, J Affect Disord, 141, 55, 10.1016/j.jad.2012.02.023

2013, So depression is an inflammatory disease, but where does the inflammation come from?, BMC Med, 11, 200, 10.1186/1741-7015-11-200

2011, Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression, Prog Neuropsychopharmacol Biol Psychiatry, 35, 664, 10.1016/j.pnpbp.2010.06.014

2014, Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis, Eur Arch Psychiatry Clin Neurosci, 264, 651, 10.1007/s00406-014-0502-z

2005, Major depressive disorder: probiotics may be an adjuvant therapy, Med Hypotheses, 64, 533, 10.1016/j.mehy.2004.08.019

2007, Impact of consuming a milk drink containing a probiotic on mood and cognition, Eur J Clin Nutr, 61, 355, 10.1038/sj.ejcn.1602546

2008, Does minocycline have antidepressant effect?, Biomed Pharmacother, 62, 308, 10.1016/j.biopha.2007.12.005

2007, Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates, J Neurosci, 27, 4894, 10.1523/JNEUROSCI.0237-07.2007

2007, What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?, Eur Arch Psychiatry Clin Neurosci, 257, 250, 10.1007/s00406-007-0728-0

2015, Neuroprotective effects of Clostridium butyricum against vascular dementia in mice via metabolic butyrate, Biomed Res Int, 41294, 12

2016, Clostridium butyricum attenuates cerebral ischemia/reperfusion injury in diabetic mice via modulation of gut microbiota, Brain Res, 1642, 180, 10.1016/j.brainres.2016.03.042

2004, Escitalopram versus citalopram: the surprising role of the R-enantiomer, Psychopharmacology (Berl), 174, 163

Thông tin
Thông tin xuất bản

Clinical Neuropharmacology

Tập 41 Số 5

151-155

Thông tin tác giả